Boehringer Ingelheim GmbH has entered into a partnership with Singapore-based Enleofen Bio Pte Ltd, to develop new therapies across a range of fibro-inflammatory diseases. The deal will give the Germany company access to Enleofen’s expertise in interleukin-11 (IL-11), a cytokine implicated in the disorders.

Eli Lilly and Company is to acquire Dermira Inc, a US medical dermatology company, for $1.1 billion in an all-cash transaction in order to expand its immunology pipeline. Dermira’s most advanced clinical programme, lebrikizumab, is a monoclonal antibody for moderate-to-severe atopic dermatitis. The company also has a marketed product for the topical treatment of primary axillary hyperhidrosis, a rare sweating disorder.